April 2019

VIVO Cannabis (TSX-V: VIVO) (OTCQX: VVCIF) reported its fourth quarter and 2018 annual financial and operating results. The company had net sales of C$9.7 million for 2018, versus net sales of C$0.9 million for 2017. Net revenue for the fourth quarter was C$5.8 million, up from C$0.3 million in the same quarter of 2017. The Green Organic Dutchman […]

by

Tweet Winter is almost over. There are officially only three Game of Thrones episodes left before the HBO series ends and we can no longer watch along as our favorite characters are brutally murdered. Or at least until the first GOT spinoff starts. But either way we need… read more at: https://www.thestranger.com/slog/2019/04/30/40065801/heylo-releases-mother-of-dragons-pot-cartridge-in-honor-of-game-of-thrones

by

LOS ANGELES, April 30, 2019 /PRNewswire/ — Nuvata, a newly established brand of premium cannabis vaporizers, today announced the launch of its first and core product line, the Mind-Body series, which delivers terpene-rich, naturally flavored cannabis oil with high THC and complimenting CBD levels for optimum balance. The Mind-Body series offers six experiences that range from […]

by

Inside MedPharm Iowa facility. (WHO-HD) Inside MedPharm Iowa facility. (WHO-HD) Iowa legalized the use of some medical marijuana in 2017, that bill allowed two manufacturers to produce it in the state. MedPharm is the first. Its General Manager Lucas Nelson says they want Iowa to lead the way, “There’s no set up list of what […]

by

Cardiol Therapeutics Inc. (TSX:CRDL,OTC:CRTPF) was featured in an article by Technical420 which covered the shift away from cannabis cultivation into a marketing, science and quality standards-based cannabis market and the company’s efforts in meeting the new standards. Cardiol Therapeutics Inc. (TSX:CRDL,OTC:CRTPF) was featured in an article by Technical420 which covered the shift away from cannabis cultivation into […]

by

Company on track to report top-line data in July/August time frame JERUSALEM, April 30, 2019 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that the last patient has completed their final visit in the Company’s pivotal Phase 3 trial (the ACCORDANCE trial) evaluating the safety and efficacy of the Accordion […]

by

Fundamentals of US Regulatory Affairs, 10th Edition For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips. BUY NOW … read more at: https://www.raps.org/news-and-articles/news-articles/2019/4/recon-pfizer-lilly-and-merck-release-first-quart

by

ACB $9.080 (0.22%) ACNNF $0.256 (1.27%) AERO $1.460 (-1.35%) AGEEF $0.575 (3.98%) ALEAF $1.130 (-3.3%) AMMJ $0.395 (2.07%) APHA $7.630 (3.25%) ARNA $45.750 (-2.74%) ATT:CNX $0.080 (0%) ATTBF $0.041 (-6.93%) AUSA:CNX $1.040 (-3.7%) AUSAF $0.782 (-3.22%) AVXL $2.970 (-4.19%) BAMM:CNX $1.870 (-15%) BBM:CNX $0.700 (-12.5%) BBRRF $0.534 (-9.47%) BE:CNX $0.100 (0%) BIO:CNX $0.530 (1.92%) BLEVF […]

by

Frequent queries from patients about the potential for cannabis oil to treat their seizures has prompted London neurologist Seyed Mirsattari to study its effectiveness. The recent surge in anecdotal stories touting the potential therapeutic benefits of cannabidiol (CBD), a non-psychoactive component in cannabis, is boosting interest in the drug, said Mirsattari, a professor at Western […]

by

A new study finds that the more cannabidiol (CBD) present in a cannabis strain, the less mental impairment this strain will produce on users. Published in the Journal of Psychopharmacology, this study is one of the first to use fMRI technology to get a glimpse of how the brain functions while under the influence of cannabis. […]

by

In what was billed by study authors as “the first insight into marijuana and opioid use over time in people with cancer across the United States,” investigators concluded that throughout a recent 10-year period, the rate of marijuana use in patients with cancer had increased, while the use of opioids by this cohort remained relatively […]

by